Australian Govt Needs To Tackle Low Biosimilar Awareness And Switching Concerns
This article was originally published in SRA
Executive Summary
The Australian government is facing something of an uphill struggle in convincing patients and healthcare professionals of the benefits of biosimilars, at least judging by a survey that has just been presented to the stakeholder reference group set up to advise on the government's biosimilar awareness strategy1.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.